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ABSTRACT

ARTICLE HISTORY

Hydroxychloroquine, initially used as an antimalarial, is used as an immunomodulatory and antiinflammatory agent for the management of autoimmune and rheumatic diseases such as systemic lupus erythematosus. Lately, there has been interest in its potential efficacy against severe
acute respiratory syndrome coronavirus 2, with several speculated mechanisms. The purpose of
this review is to elaborate on the mechanisms surrounding hydroxychloroquine. The review is
an in-depth analysis of the antimalarial, immunomodulatory, and antiviral mechanisms of
hydroxychloroquine, with detailed and novel pictorial explanations. The mechanisms of hydroxychloroquine are related to potential cardiotoxic manifestations and demonstrate potential
adverse effects when used for coronavirus disease 2019 (COVID-19). Finally, current literature
associated with hydroxychloroquine and COVID-19 has been analyzed to interrelate the mechanisms, adverse effects, and use of hydroxychloroquine in the current pandemic. Currently, there
is insufficient evidence about the efficacy and safety of hydroxychloroquine in COVID-19.

Received 5 August 2020
Revised 13 September 2020
Accepted 19 September 2020
KEYWORDS

Hydroxychloroquine; COVID19; cardiotoxicity;
mechanism of action

KEY MESSAGES

1.
2.
3.

HCQ, initially an antimalarial agent, is used as an immunomodulatory agent for managing
several autoimmune diseases, for which its efficacy is linked to inhibiting lysosomal antigen
processing, MHC-II antigen presentation, and TLR functions.
HCQ is generally well-tolerated although severe life-threatening adverse effects including
cardiomyopathy and conduction defects have been reported.
HCQ use in COVID-19 should be discouraged outside clinical trials under strict medical
supervision.

Introduction
Initially used to treat malaria, hydroxychloroquine
(HCQ) is an important therapeutic option for several
autoimmune diseases, especially systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The efficacy of HCQ in rheumatic illnesses stems from its antiinflammatory and immunomodulatory effects, the
mechanisms of which are unclear. Although initially
thought to exert its immunomodulatory effects by
interfering with lysosomal enzymatic actions and
major histocompatibility complex class-II (MHC-II)CONTACT Amandeep Goyal

agoyal3@kumc.eduPhone

mediated antigen presentation, emerging evidence
suggests interference with Toll-like receptor (TLR)
functions as an additional pathway [1].
HCQ is one of the safest immunomodulatory agents
for rheumatic illness. However, rare but serious
adverse effects have been reported, mostly with longterm use. HCQ-induced acquired lysosomal storage
disease causes some of these adverse effects, including myopathy and cardiomyopathy [1]. Corrected QT
(QTc) interval prolongation is associated with HCQ
owing to human ether-a-go-go-related gene (hERG)
voltage-gated potassium channel inhibition [2].
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Figure 1. Antimalarial actions of hydroxychloroquine (HCQ). Being lipophilic, HCQ easily permeates the red blood cell that contains the malaria parasite and enters the food vacuole of the parasite. Being weakly alkaline, HCQ increases the pH of the food
vacuole, which inhibits the conversion of toxic haem to non-toxic hemozoin. Accumulation of toxic haem leads to membrane lysis
and parasite death.

In vitro studies [3–7] have revealed the antiviral
properties of HCQ, raising interest in its potential
therapeutic role in coronavirus disease 2019 (COVID19). As of 30 August 2020, 24,854,140 cases of COVID19 were reported with 838,924 deaths globally according to the World Health Organization (WHO) [8] and
currently there is no effective treatment for this novel
disease. Although HCQ was among the first drugs
evaluated for COVID-19 treatment, clinical trials [9]
reported so far have largely been inadequate to confirm its efficacy owing to poor methodology and small
sample sizes. Furthermore, recent studies [10–15] have
raised concerns about the safety of HCQ, especially in
combination with other drugs.
This review illustrates the mechanisms of action
underlying the antimalarial, immunomodulatory, and
potentially antiviral properties of HCQ, and the pathophysiological aspects of HCQ-mediated cardiotoxicity,
with novel pictorial explanations. Additionally, the

controversial role of HCQ for COVID-19 treatment is
summarized with currently available clinical trials.

Search strategy and selection criteria
Data for this review were identified by searches of
MEDLINE, PubMed, EMBASE, SCOPUS, Google Scholar,
Science Citation Index and references from relevant
articles using the search terms “hydroxychloroquine,”
“severe acute respiratory syndrome coronavirus 2,”
“SARS-CoV-2,” “COVID-19,” “2019-nCoV,” “Wuhan,” and
“coronavirus.” Only articles published in English from
inception to 31st August 2020, restricted to humans,
and directly related to this review were included.

Indications of HCQ
Antimalarials have been used for the treatment of RA
since the 1950s. HCQ is one of the mildest and
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Figure 2. Immunomodulatory actions of hydroxychloroquine (HCQ). In antigen-presenting cells, HCQ increases the pH of lysosomes and inhibits lysosomal proteases, thereby inhibiting antigen processing and presentation to major histocompatibility complex class-II proteins (MHC-II). HCQ increases the pH of the late endosome loading compartment that contains MHC-II, which
inhibits the clipping and replacement of the invariant chain (Ii) by antigenic peptides and prevents the formation of the MHC-II/
peptide complex, thereby inhibiting MHC-II-mediated antigen presentation to CD4þ T-cells. In plasmacytoid dendritic cells, HCQ
inhibits immune complex-mediated Toll-like receptor (TLR) 7 and 9 in the endosome by increasing the pH of the endosome and
directly inhibiting the binding of the immune complex to the TLR 7 and 9, thereby preventing downstream type-1 interferon transcription. HCQ promotes T-cell apoptosis and inhibits B-cell antigen processing, thereby decreasing T-cell- and B-cell-mediated
cytokine release.

safestdisease-modifying antirheumatic drugs [16].
Although initially used predominantly for RA, HCQ
may be most efficacious in SLE, for which besides
treating skin and joint disease, HCQ prevents disease
flares, promotes long-term survival, and improves
overall prognosis [17]. Furthermore, the antithrombotic
effects of HCQ are beneficial in patients with SLE and
anti-phospholipid syndrome [18,19]. HCQ may have
utility in several infectious disease processes. Although
the overall efficacy of HCQ in infectious diseases,
besides malaria, is unknown, HCQ is being explored in
human immunodeficiency viruses, Coxiella burnetii,
Zika virus, chikungunya, and Whipple’s disease [18].

Mechanisms of action
HCQ and chloroquine (CQ) are 4-aminoquinolines with
similar chemical structures, except for an ethyl group

substitution by a hydroxyethyl group on the tertiary
amino acid side chain in HCQ. HCQ, 2-[[4-[(7-chloro-4quinolyl)amino]pentyl]ethylamino]ethanol
sulphate
[20], has antimalarial and immunomodulatory properties. HCQ is absorbed rapidly after oral administration
and has a long half-life of 30–60 days, reaching steady
plasma levels up to 6 months after therapy initiation
[21]. HCQ can be detected in plasma and tissues several months to years after discontinuation [22]. HCQ is
metabolized in the liver by CYP450 and undergoes
renal excretion.

Antimalarial action
HCQ was widely used as an antimalarial agent before
the rapid development of drug-resistance. In malaria,
HCQ acts as a blood schizonticide against trophozoites
in red blood cells (RBCs). In RBCs, a trophozoite
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obtains the amino acids required for growth by
haemoglobin breakdown in its food vacuole. A byproduct of this breakdown is haem (ferriprotoporphyrin IX), which is toxic to the parasite as it lyses cell
membranes. In the food vacuole, this toxic haem is
converted to non-toxic crystallized hemozoin [23].
The antimalarial action of HCQ is dependent on its
lipophilicity to permeate and accumulate in intracellular structures, including lysosomes and food vacuoles
of the malaria parasite. Once inside an intracellular
vesicle, HCQ increases the pH as a weak base [24]. By
increasing food vacuole pH, HCQ interferes with the
conversion of haem to hemozoin, thereby increasing
the toxic haem level, which lyses the parasite (Figure
1) [18].

Immunomodulatory and anti-inflammatory action
Although HCQ is efficacious in several autoimmune
and inflammatory disorders, including SLE and RA, the
exact mechanism underlying the anti-inflammatory
and immunomodulatory actions of HCQ is unclear.
Being lipophilic, HCQ easily permeates cell membranes and accumulates in intracellular vesicles,
including lysosomes, endosomes, and autophagosomes. In these acidic vesicles, it interferes with vesicular enzyme functionality (such as proteases) by
increasing the pH [25]. In antigen-presenting cells
(APCs), HCQ interferes with the processing of antigens
to peptides, thereby preventing peptide presentation
for MHC-II [1,26]. Furthermore, in the loading compartment of MHC-II-containing acidic endosomes, HCQ
possibly interferes with the interaction of peptides
with MHC-II. A crucial step in this interaction is the
clipping of the MHC-II invariant chain and replacement
by antigen peptides, which forms the MHC-II/peptide
complex. An increase in pH caused by HCQ inhibits
invariant chain clipping by proteases. This selectively
inhibits the binding of low-affinity self-antigen peptides to the MHC-II binding site but not of high-affinity
foreign-antigen peptides (such as bacterial peptides),
possibly explaining why HCQ is not associated with an
increased infection risk [1,21] (Figure 2).
Thus, by interfering with MHC-II-related autoantigen
presentation to cluster of differentiation (CD) 4þ Tcells via APCs, HCQ interferes with cytokine release.
This action also interferes with B-cell activation by
CD4þ T-cells. Additionally, HCQ induces apoptosis of
autoreactive T-cells and interferes with antigen processing by B-cells, thereby interfering with their functions and cytokine production (interleukin [IL]-1, IL-6,

interferon-gamma, tumour necrosis factor [TNF], and
B-cell activating factor) [21,27].
A recently highlighted immunomodulatory mechanism associated with HCQ is the inhibition of TLR signalling pathways [28]. Immune complexes that contain
DNA or RNA bind Fc-gamma receptor-II on plasmacytoid dendritic cells and are internalized to endosomes
that contain intracellular TLR7 and TLR9, which recognizes single-stranded RNA and DNA respectively. The
binding of immune complexes to TLR7 and TLR9 leads
to the downstream induction of type-1 interferon transcription through the myeloid differentiation primary
response protein 88. The pathogenic role of type-1
interferons in various rheumatic diseases, such as SLE,
has been well described [29]. Type-1 interferons activate T-cells, B-cells, natural killer cells, myeloid dendritic cells, and monocytes, leading to further cytokine
production [1,21]. HCQ accumulates in TLR7 and TLR9containing endosomes and directly inhibits the binding of TLR7 and TLR9 to the immune complexes. By
increasing the pH of the endosome, HCQ can also
interfere with TLR processing [30]. Thus, by interfering
with TLR7 and TLR9 signalling, HCQ inhibits the transcription of type-1 interferons, which results in immunomodulatory and anti-inflammatory effects [1,21]
(Figure 2).

Antiviral action
Owing to the current COVID-19 pandemic, several
therapies are under investigation for potential efficacy
against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) using current and historical data. In
vitro studies have shown potential antiviral properties
associated with HCQ and CQ, raising interest in their
role as potential therapies against SARS-CoV-2. The
anti-inflammatory action of HCQ is dependent on
immunomodulation and the downstream production
of cytokines. The attenuation of inflammation results
in a successful response in a rheumatic setting and
possibly SARS-CoV-2 infection [31]. Furthermore, successful SARS-CoV-2 entry into host cells is strongly
dependent on angiotensin-converting enzyme-2 (ACE2) interaction with the viral spike protein [32]. CQ
reduces the glycosylation of ACE-2, which inhibits the
binding of the SARS-CoV-2 spike protein to the cell
surface and cell integration [33,34]. Recent investigation also suggests that by binding the gangliosides,
HCQ inhibits communication between the spike protein and the cell membrane, thus inhibiting viral entry
into the cell [33]. Additionally, HCQ and CQ accumulate in lysosomes and, by increasing the pH of
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Figure 3. Proposed theoretical antiviral actions of hydroxychloroquine (HCQ). By increasing the pH of the lysosome, HCQ may
inhibit endosomal acidification to prevent viral RNA shedding into the cytoplasm, thereby interfering with downstream viral replication. HCQ may bind the gangliosides and inhibit the communication between the spike protein and the cell membrane, thus
inhibiting viral entry into the cell.

lysosomes, prevent viral particle release by disrupting
vital cellular pathways [34]. Moreover, the inhibition of
glycosyl-transferases, post-translational viral modification, quinone reductase-2 and sialic acid synthesis,
and viral replicative mechanisms is implicated in the
antiviral effect of HCQ (Figure 3) [31]. However, to
date, no in vivo studies have confirmed the potential
antiviral action of HCQ in humans.

Adverse effects
HCQ is widely used in rheumatology and is generally
safe and well-tolerated; however, several adverse
effects have been reported, some irreversible and lifethreatening [35].

Cardiotoxicity
Cardiomyopathy and conduction abnormalities with
HCQ have been described and recently highlighted
with its use for COVID-19. Unlike cardiomyopathy,
which is rare and occurs after prolonged exposure to
HCQ, conduction abnormalities are common and acute
(Figure 4) [36].
Acquired lysosomal storage disease induced by
HCQ is the pathogenetic pathway for the

development of cardiomyopathy, mostly with longterm use [37]. Most cases are caused by accumulation,
which can be augmented by CYP450 2C8 mutation
[38]. Being lipophilic, HCQ easily permeates myocytes,
in which it binds lysosomal phospholipids, leading to
lysosomal
accumulation
of
phospholipids.
Furthermore, by increasing the pH of the lysosome,
HCQ inhibits lysosomal enzymes, such as hydrolases
and phospholipases, which interferes with lysosomal
function and exocytosis, leading to the accumulation
of glycogen and phospholipids [39]. The abnormal
accumulation of metabolic products and lysosomal
inclusions in cardiac myocytes induces an acquired
lysosomal storage disease, leading to myofibrillar disorganization, atrophy, and fibrosis, which may lead to
cardiomyopathy [40]. Acquired lysosomal storage disease can be visualized by electron microscopy as
vacuoles, myeloid bodies, and curvilinear bodies.
Although vacuoles are more commonly detected,
curvilinear bodies are pathognomonic of HCQ-induced
lysosomal storage disease. Histopathologically, HCQinduced lysosomal storage disease appears identical to
inherited lysosomal storage diseases, including
Anderson-Fabry disease, except for the presence of
curvilinear bodies [41]. The most frequent clinical presentation is acute exacerbation of right, left, or
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Figure 4. Hydroxychloroquine (HCQ)-induced cardiomyopathy and myopathy. HCQ permeates the lysosomes of myocytes and
causes glycogen and phospholipid accumulation by binding phospholipids and increasing the pH, thereby inhibiting phospholipases and hydrolases. This leads to the formation of curvilinear and myeloid bodies and cytoplasmic vacuoles causing an acquired
lysosomal storage disease, which causes fibrillar disorganization, atrophy, and fibrosis. These changes lead to cardiomyopathy and
proximal myopathy in skeletal muscles. HCQ-induced conduction abnormalities. HCQ binds Ikr (hERG) potassium channels, slowing
potassium efflux in phase 2 and especially phase 3, thereby prolonging the action potential duration that leads to QTc prolongation (depicted in red). The action potential begins with sodium influx, phase 0; rapid potassium efflux, phase 1; calcium influx balanced by potassium efflux, phase 2; potassium efflux, phase 3; and subsequent restoration of resting membrane potential,
phase 4.

biventricular heart failure. Risk factors for the development of HCQ-induced cardiomyopathy include prolonged exposure to the drug (several years), elderly
age, renal insufficiency, and chronic liver disease.
Diffusely thickened ventricular walls on a transthoracic
echocardiogram are hallmarks of this cardiomyopathy,
although this is not specific to HCQ-induced cardiomyopathy [42,43]. A cardiac magnetic resonance image
(MRI) that shows late gadolinium enhancement is a
marker for fibrosis, especially in hypertrophic cardiomyopathy, and prognostic marker for cardiac death.
MRI can also be used to guide biopsy sampling;

hence, MRI plays an important role in cardiac evaluation and risk stratification [44]. Endomyocardial
biopsy with electron microscopy is the most specific
diagnostic test [45]. Fortunately, most patients report
symptom resolution after drug cessation [46].
HCQ-induced conduction disorders are usually
acute, owing to cardiac channel blockage. Several
structurally-related medications, such as quinolones,
CQ, and HCQ, that affect myocardial depolarization
and repolarization mainly via cardiac Kþ channel
blockage cause QT/QTc prolongation, which is an indicator of an increased risk of drug-induced torsade de
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Table 1. Summary of in vitro studies with hydroxychloroquine and chloroquine in coronaviruses.
Date
August 2004
August 2005
February 2020
March 2020
April 2020

Authors

Results

Keyaerts et al. [3]
Vincent et al. [4]
Wang et al. [5]
Yao et al. [6]
Andreani et al. [7]

CQ inhibits SARS-CoV
CQ inhibits SARS-CoV
CQ inhibits SARS-CoV-2
HCQ > CQ against SARS-CoV-2, dosage recommendations
HCQ and AZ show synergistic effect against SARS-CoV-2

pointes (TdP). TdP is usually self-limiting but can degenerate into lethal ventricular fibrillation and cause sudden
cardiac death [38]. The main mechanism of HCQ-induced
QT prolongation is blockage of hERG Kþ channels [47].
hERG, located on chromosome 7 q35-36, encodes the
pore-forming subunits of hERG Kþ channels, which
mediate rapid delayed rectifier potassium currents (Ikr),
resulting in phase 2 and phase 3 of repolarization in the
cardiac cycle. The blockage of hERG Kþ Ikr channels
increases the duration of phase 2 and especially phase 3
repolarization, leading to a prolonged QT interval (class
III antiarrhythmic effect) [2]. Additionally, HCQ can cause
hypotension owing to alpha blockade, leading to arteriolar and venular dilation, sodium (class 1 antiarrhythmic
effect) and calcium channel blockage, and a negative
inotropic effect at low micromolar concentrations [2].
These effects explain the reduction in the maximum velocity of cardiac action potential and conduction disturbances, such as atrioventricular block, bundle branch
block, and a QT prolongation effect [38]. HCQ blocks cardiac channels in a dose-dependent manner. At the currently recommended dose of less than 5 mg/kg/day,
HCQ is usually safe, although prolongation of the QT/
QRS is rarely observed on a surface electrocardiogram
[48]. Ventricular ectopy and lethal ventricular arrhythmias
have been reported, mostly with supra-therapeutic
doses. Risk factors for the development of lethal ventricular arrhythmias include underlying structural heart
disease, electrolyte abnormalities (e.g. hypokalaemia and
hypomagnesemia), female sex, elderly age, genetic
defects of cardiac ion channels (inherited long QT syndrome owing to hERG mutation), renal insufficiency,
chronic liver disease, and, concomitant use of other
drug classes that cause QT prolongation, such as azithromycin (AZ) [2]. A QT/QTc interval of over 500 ms is associated with a higher risk of TdP and sudden cardiac
death. The risk of cardiotoxicity secondary to HCQ is theoretically greater in critically ill patients with COVID-19
owing to the potential for viral myocarditis, cardiac
injury owing to cytokine storm, and multiorgan failure [47].

Other adverse effects
HCQ-induced ocular toxicity has been recognized,
especially Bilateral bull’s eye maculopathy with central

macular involvement sparing the parafovea, which is
observed rarely (< 1%) in the first 5 years of therapy,
in < 2% of cases after 10 years, and in up to 20% of
cases after 20 years [49,50]. HCQ binds melanin in the
retinal pigment epithelium (RPE) and accumulation
results in macular damage. Furthermore, by increasing
RPE lysosome pH and inhibiting lysosomal enzymes
and phagocytosis, HCQ inhibits the clearance of shed
outer photoreceptor segments, leading to accumulation. This leads to the migration of pigment-containing RPE cells to outer retinal layers, and in the loss of
photoreceptors and RPE atrophy. Damage to the outer
retinal photoreceptor layer precedes RPE damage and
atrophy according to optical coherence tomography
data. HCQ-induced retinopathy is irreversible and may
continue for several months after drug discontinuation
owing to its long half-life [49,51]. HCQ can also bind
cellular lipids in the cornea and deposit in the corneal
basal epithelial layer leading to corneal deposition
(vortex keratopathy), which is reversible after drug discontinuation. Other ocular adverse effects include ciliary body deposition leading to disturbances in
accommodation and blurred vision, which are also
reversible [52].
Proximal myopathy, possibly associated with neuropathy, owing to HCQ has been reported, with a similar
pathogenesis
to
that
of
HCQ-induced
cardiomyopathy, i.e. acquired lysosomal storage disease (Figure 4). Risk factors include higher cumulative
dose, elderly age, and renal disease. HCQ-induced
myopathy presents with proximal weakness with normal creatine phosphokinase levels but abnormal electromyogram and muscle biopsy results that reveal
vacuoles, myeloid bodies, or curvilinear bodies, the latter being the most specific to this disease [53]. HCQinduced myopathy is usually reversible, with rapid clinical improvement after drug discontinuation [54].
Other adverse effects of HCQ include gastrointestinal distress (e.g. nausea, vomiting, diarrhoea, abdominal pain, and anorexia) and skin rash, which are
common and observed in 5–10% of patients administered with HCQ [16,55]. Rare adverse effects include
skin hyperpigmentation, alopecia, agranulocytosis,
aplastic anaemia, leukopoenia, thrombocytopenia,
haemolytic
anaemia
in
glucose-6-phosphate
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dehydrogenase deficiency, irritability, nervousness,
headaches, dizziness, vertigo, tinnitus, and transaminitis [56].

COVID-19 and HCQ literature review
In December 2019, China reported a novel viral illness
caused by SARS-CoV-2, later defined by the WHO as
COVID-19. HCQ gained interest as a potential therapeutic option for COVID-19 based on in vitro studies
suggesting efficacy of HCQ and CQ against SARS-COv
and SARS-Cov-2 [3–7] (Table 1). Although the initial
studies showed potential efficacy, these had several
flaws and the risk of bias and several further trials
failed to confirm the efficacy of HCQ for COVID-19.

Studies suggesting HCQ efficacy in COVID-19
HCQ efficacy investigation began with a French investigation of 36 patients [57]. The investigation claimed
efficacy of HCQ ± AZ in COVID-19 as significantly more
patients administered HCQ ± AZ had negative polymerase chain reaction (PCR) results on Day 6 than those
not administered HCQ. However, this study had several major limitations, including small sample size, lack
of randomization and blinding, heterogeneous patient
recruitment,
and
poorly
selected
endpoints.
Furthermore, the six patients lost to follow-up were all
in the treatment arm, some with adverse outcomes.
Despite several significant concerns with the methodology, this study gained widespread attention that led
to the use of HCQ in patients with COVID-19. Another
study by the same authors evaluated the efficacy of
HCQ with AZ in 80 patients with COVID-19 and
showed efficacy in 65 patients [58]. However, a significant pitfall of this study was the lack of a control arm.
Furthermore, the viral PCR threshold value, which
determined patient discharge from the hospital, was
changed multiple times during the study.
The first randomized controlled trial (RCT) suggesting efficacy of HCQ in COVID-19 was reported by
Chen et al., who reported a shorter duration of symptoms (fever and cough) and radiographic improvements in patients with mild COVID-19 treated with
HCQ for 5 days compared with those with standard of
care treatments [59]. However, this study was also limited by sample size (31 patients in each arm), strict
inclusion criteria excluding severe cases, which raises
concerns of selection bias. Additionally, clinical
improvement was assessed by only fever and cough,
excluding other important outcomes, such as oxygen
saturation. Another open-label RCT by Chen et al.

suggested shorter time to clinical recovery which was
5.50 days in CQ arm (n ¼ 18), 6.00 days in HCQ arm
(n ¼ 18) and 7.50 days in control arm (n ¼ 12). Besides
the small sample size, this study was nonblinded.
Further, the study was terminated early and was
underpowered [60].
The recent evidence about the efficacy of HCQ in
COVID-19 has been through retrospective case series
or retrospective non-randomized, non-blinded observational studies. Ahmad et al. reported clinical recovery defined as improvement in fever and dyspnoea in
85% of the patients hospitalized with COVID-19 when
treated with HCQ and doxycycline. This case series
had a small sample size (n ¼ 54) with no control arm.
Further, 14.8% (8) patients in this study clinically
deteriorated or died and radiographic improvement
was observed only in 11% of the patients [61]. Million
et al. reported “good clinical outcome” and virological
clearance in 917% out of 1,061 patients with COVID19 treated with HCQ þ AZ [62]. However, drawbacks of
this retrospective case series included no control arm,
poorly defined clinical outcomes, unsupervised treatment, and incomplete data with computed tomography scans and serum drug levels unavailable in
some cases. Yu et al. reported decreased mortality
(1888% vs 458%) and reduced IL-6 levels with the
use of HCQ in 48 critically ill patients with COVID-19
[63]. Antivirals were used in several patients and significantly more patients receiving interferon and antibiotics in the non-HCQ group than in the HCQ group.
Additionally, with the cause of mortality not specified,
drug interactions and comorbidities could have influenced the results. Novales et al. reported decreased
mortality in patients treated with HCQ (27 out of 123,
22%) compared to the control arm (21 out of 43,
48.8%) in a retrospective analysis in patients admitted
with COVID-19. Besides small sample size, lack of
blinding and retrospective study method, other limitations of this study included use of other antiviral and
anti-inflammatory medications, younger patients in
the HCQ arm (61.5 years vs 68.7 years), and cause of
mortality not specified [64]. A large retrospective
population wide analysis of patients with confirmed/
suspected COVID-19 from Portugal compared the incidence of PCR positivity in those who were already on
HCQ to those who were not [65]. About, 0.29% of all
patients who tested positive for COVID-19 were on
HCQ while 0.36% of all patients who tested negative
were on HCQ. No data was available about patient
comorbidities, and drug compliance in this retrospective analysis. A direct causation effect could be
deduced based on this retrospective observational

Case series

Yu et al. [63]

Bessiere et al. [10]

Chorin et al. [12]

Mercuro et al. [15]
Mallat et al. [67]

Gianfrancesco et al. [98]

Novales et al. [64]
Million et al. [62]
Geleris et al. [75]
Rosenberg et al. [80]

May 2020

May 2020

May 2020

May 2020
May 2020

May 2020

May
May
May
May

Cohort
Cohort

Mahevas et al. [72]
Singh et al. [78]

Ip et al. [77]
Ferreira et al. [65]
Paccoud et al. [74]
Faico-Filho et al. [69]
Boulware et al. [95]
Sbidian et al. [76]
Chen L et al. [60]
Arshad et al. [66]
Lecronier et al. [73]

Horby et al. [90]

Cavalcanti et al. [88]
Mitja et al. [87]
Chen CP et al. [86]

May 2020
May 2020

May 2020
June 2020
June 2020
June 2020
June 2020
June 2020
June 2020
June 2020
July 2020

July 2020

July 2020
July 2020
July 2020

RCT
RCT
RCT

RCT

Cohort
Cohort
Cohort
Cohort
RCT
Cohort
RCT
Cohort
Cohort

RCT

Tang et al. [85]

Cohort
Case series
Cohort
Cohort

Case series

Cohort
Cohort

Case series

Case series
Case series

May 2020

2020
2020
2020
2020

Cohort

Ramireddy et al. [13]
Ahmad et al. [61]

April 2020
May 2020

Case series
Cohort

Saleh et al. [14]
Magagnoli et al. [79]

Study type
Cohort
RCT
RCT
Case series
Case series
Case series
Case series

April 2020
April 2020

Authors

Gautret et al. [57]
Chen J. et al. [84]
Chen Z. et al.[59]
Molina et al. [68]
Gautret et al. [58]
Mathian et al.[97]
Chorin et al. [11]

March 2020
March 2020
March 2020
March 2020
April 2020
April 2020
April 2020

Date

667
293
32

4716

2512
360304
84
66
821
4642
48
2541
80

181
3372

150

166
1061
1376
1438

600

90
34

251

40

568

98
54

201
368

36
30
62
11
80
17
84

N

Study results (HCQ associated with:)

QTc prolongation
Dealy in viral clearance, no improvement in
lab-markers
No reduction in hospitalization in patients with
rheumatic diseases
Improved mortality
Improved viral clearance, mortality, clinical outcomes
No improvement in mortality, intubation
No improvement in clinical outcomes or mortality
in inpatients
No improvement in viral clearance, time to
clinical recovery
No improvement in ICU transfer, mortality
No improvement in mortality and need for
mechanical ventillation
No improvement in mortality
Less odds of PCR positivity
No improvement in clinical outcomes
No improvement in viral clearance
No efficacy as post-exposure prophylaxis
No improvement in mortality
Improved time to clinical recovery
Improved mortality
No improvement in clinical outcomes or mortality in
ICU patients
No improvement in mortality, more death and
ventillation in non-ventillated patients
No improvement in clinical status
No improvement in viral clearance
No improvement in viral clearance

QTc prolongation

Improved mortality and decreased IL-6 levels in
critically ill
QTc prolongation

QTc prolongation
No improvement in mortality, intubation. Increased
all-cause mortality
QTc prolongation
Improved clinical recovery

Improved viral clearance
No improvement in viral clearance, mortality
Improved time to clinical recovery
No improvement in viral clearance
Improved clinical course and viral clearance
No impact on clinical course in patients with SLE
QTc prolongation

Table 2. Summary of COVID-19 studies involving hydroxychloroquine.
Study limitations

(continued)

Unblinded, protocol deviation
Unblinded, unequal use of other medications, younger patients
SS, exclusion of severe illness, antivirals used

More severe illness, therapy initiated after prolonged illness

Obs, no randomization, variation in HCQ prescribing patterns
Obs, missing information on comorbidities, compliance
Obs, SS, no randomization,
Obs, SS, variable time for serial sampling
Case definiation limitation, lack of uniform PCR testing
Obs, lack of direct information on study variables
SS, unblinded, terminated early, underpowered
Obs, effect of other medications
Obs, SS, unblinded, more severe illness

Obs, no randomization, potential baseline confounders
Obs, potential baseline confounders

Open label, antivirals in both arms, patients switched arms

Obs, Retrospective analysis, focus beyond HCQ in rheumatic
populations
Obs, SS, use of other medications, potential baseline confounders
Obs, No control arm, therapy unsupervised, incomplete data
Obs, HCQ arm with older age, more comorbidities
Obs, only in-hospital deaths measured

Obs, Early discontinuation, use of other cardiotoxic drugs, ICU
patients, CM
Obs, No control arm, effect of other medications, severity of
illness, CM
Obs, SS, no control arm
Obs, SS, exclusion of severe illness

Obs, no control arm
Obs, no control arm, clinically worsened patients not included in
final analysis
Obs, use of antivirals. Unequal use of other medications

Obs, SS, no randomization, unblinded, LTFU all in HCQ group
SS, no intervention unifromity, antivirals used
SS, severe cases excluded, inadequate primary end points
Obs, SS, no control arm, short follow up
Obs, SS, no control arm, changes to viral PCR threshold
Obs, SS, obs., Rheumatic population
SS, no control arm, effect of other medications, severity of
illness, CM
Obs, no control arm
Obs, all male, more severe cases received HCQ þ/- AZ

ANNALS OF MEDICINE
125

SS: small sample; obs.: observational limitations; CM: co-morbidities; LTFU: Lost to follow up; N-PCR: Nasopharyngeal Polymerase Chain Reaction; Green: Showing efficacy of HCQ; Red: Showing no efficacy of
HCQ; Yellow: Studying adverse effects of HCQ.

Obs., No control arm, exclusion of severe illness
Unblinded, younger, healthier, male patients with mild illness.
219
500
Jaimez et al. [100]
Kamran et al. [89]
August 2020
August 2020

Case series
RCT

Lofgren et al. [101]
August 2020

RCT

2719

Delayed and decreased chances of
virological clearance
More GI adverse effects (mild), no ventricular
arrythmias or sudden cardiac death
Significant but not clinically relevant QTc prolongation
No improvement in disease progression and
PCR conversion
85
Cohort
Saleemi et al. [71]
August 2020

Study limitations

Obs, SS, short follow up, exclusion of severe illness
Obs, variability in standard of care, unequal use of other
medications
Obs, SS, unequal use of other medications, potential baseline
confounders
Younger healthier participants, exclusion of severe illness
Komissarov et al. [70]
Peters et al. [81]
July 2020
August 2020

Cohort
Cohort

43
1893

No improvement in symptom duration or severity in
outpatients
No improvement in viral clearance
No improvement in mortality

Study results (HCQ associated with:)
N

432
RCT

Study type
Authors

Skipper et al. [78]
July 2020

Date

Table 2. Continued.
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Lack of uniform PCR testing, healthier and lower-risk participants
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analysis [65]. A recent multicenter retrospective analysis of HCQ ± AZ in 2,541 inpatients with COVID-19
reported significantly lower mortality in patients
treated with HCQ alone (13.5%), or in combination
with AZ (20.1%) than in patients in the control arm
(26.4%) [66]. However, significantly more patients
received corticosteroids (789% and 743% versus
357%) and tocilizumab (34% and 92% versus 12%)
in the HCQ and HCQ þ AZ arms than in the control
arm. Furthermore, significantly more patients were
more than 65 years old (614% versus 489% and
455%) in the control arm than in the HCQ and
HCQ þ AZ arms. Although propensity score matching
suggested a 51% decline in the mortality hazard ratio
in patients who received HCQ, unmeasured biases
may exist, in addition to the limitations of a nonrandomized, non-blinded observational trial.

Studies suggesting no efficacy of HCQ for COVID19 treatment
Several retrospective cohort analyses have failed to
show efficacy of HCQ in virological clearance of
COVID-19. Mallat et al. reported a delay in virological
clearance in patients with COVID-19 treated with HCQ
[67]. No improvement in lymphopenia or inflammatory
markers was observed. This study was limited by small
sample size (21 in HCQ and 13 in control arm) and
exclusion of severe illness. A small case series of 11
patients with COVID-19 treated with HCQ þ AZ
revealed no virological clearance in eight patients
5–6 days after treatment [68]. The small sample size,
lack of a control arm, and short follow-up were the
limitations of this study. A prospective study measuring consecutive viral loads in 66 patients admitted
with moderately severe COVID-19 did not find any difference in viral load clearance over time in vivo with
use of HCQ compared to those not treated with HCQ
[69]. Again, small sample size and variation in time for
serial sampling were some limitations with this study.
Similarly, another observational study evaluated the
effect of HCQ on seroconversion in 43 patients with
mild COVID-19 by PCR on Days 0.3 and 8 [70] and did
not find any association of HCQ use with increase or
decrease in viral RNA copy number. Small sample size,
short follow up and exclusion of more severe disease
were some of the limitations of this study. A retrospective observational study (n ¼ 85) actually reported
that use of HCQ þ AZ was associated with decreased
and delayed virological clearance, with median time to
negative PCR being 23 days in HCQ þ AZ arm and
19 days in control arm, and 77% patients in HCQ þ AZ
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arm compared to 100% patients in control arm being
PCR negative at Day 28 [71]. Again, small sample size
in addition to a younger patient population, unequal
use of other medications, and more symptomatic
patients in HCQ þ AZ arm were some limitations of
this study.
Lack of efficacy of HCQ in clinical outcomes of
COVID-19 has been observed in many retrospective
cohort analyses. An observational study in patients
with COVID-19, who required oxygen but not in an
intensive care unit, from France did not observe any
difference in clinical outcomes (survival or transfer to
intensive care unit) in 84 patients who received HCQ
and 89 patients who did not [72]. Furthermore, more
patients had QTc prolongation in the HCQ arm than in
the control arm. A retrospective observational study in
80 patients admitted to the ICU with severe COVID-19
did not find any difference in clinical outcomes (need
for treatment escalation), ventilator free days, and
mortality between the HCQ and control arm [73].
Another retrospective observational study (n ¼ 84) in
patients admitted with COVID-19 did not find any difference in risk of unfavourable clinical outcomes
(death or transfer to ICU) in patients treated with HCQ
and control arm [74]. Another observational analysis of
1,376 patients from New York determined that HCQ
has no significant impact on intubation or death [75].
Although this analysis used a large sample size ensuring power, the confounding bias of unmeasured variables, such as older age and more comorbidities in the
HCQ arm, must be considered. A retrospective cohort
analysis of 4642 patients from France did not find any
mortality benefit of HCQ ± AZ in patients hospitalized
with COVID-19 [76]. Limitations of this study included
more comorbidities in HCQ and HCQ þ AZ arms, and
lack of direct information on drug doses and study
variables such as oxygen requirement. In another
retrospective observational study of 2512 patients hospitalized with COVID-19, no difference in mortality rate
was seen in patients prescribed HCQ ± AZ [77].
Significantly more patients who received HCQ were
younger and less likely to be nursing home residents,
although were more symptomatic. Further, there were
variations in dosing, duration, and prescribing patterns
of HCQ. Another large retrospective cohort analysis of
inpatients with COVID-19 did not find any improvement in mortality or need for mechanical ventilation
in those treated with HCQ ± AZ [78]. There were significant differences in baseline characteristics of the
patients in either arm in this study. An investigation of
368 males in a Veterans Affairs hospital suggested no
mortality benefit from HCQ ± AZ. The observers also
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suggested an increase in all-cause mortality with HCQ
use [79]. Although a large sample was evaluated, the
study population was all-male with more severe cases
receiving HCQ ± AZ, possibly skewing the observed
mortality increase with HCQ. A retrospective analysis
of 1,438 New York hospital patients observed no significant difference in in-hospital mortality in patients
receiving HCQ, AZ, and HCQ þ AZ compared to no
treatment [80]. As this was observational within a specific setting, the analysis of other hospital visits after
discharge was limited. Only in-hospital deaths were
measured, leaving the possibility for unmeasured
deaths in another setting or hospital. A large multicenter retrospective analysis from the Netherlands
(n ¼ 1893) showed no difference in 21-day mortality in
patients treated at hospitals that routinely used HCQ
or CQ in patients admitted with COVID-19, compared
to hospitals that did not [81]. Another study that suggested no survival benefit and increased risk of ventricular arrhythmias in patients with COVID-19 owing
to HCQ or CQ was retracted owing to significant concerns with the accuracy of data acquisition and analysis [82,83]. Although retrospective analyses as
mentioned above have the benefit of rapidly evaluating a hypothesis, several limitations exist including
lack of randomization, risk of selection bias and confounding bias of unmeasured variables.
The first RCT evaluating the role of HCQ in COVID19 by Chen et al. reported no benefit of HCQ in virological clearance, as 867% of patients in the HCQ arm
and 90% in the conventional arm were nasopharyngeal swab PCR negative for SARS-CoV-2 by Day 7 [84].
No significant differences were noted in the resolution
of fever or radiographic progression between groups.
However, this study had several limitations, including
the small sample size (15 patients in each arm), lack of
intervention uniformity, and use of antiviral agents.
Tang et al. also did not find any significant difference
in clinical improvement time or PCR negativity in 70
patients treated with HCQ compared with 80 treated
with the standard of care [85]. This study was openlabel and antiviral treatments were used in both arms.
Furthermore, the initial intention to treat protocol was
not followed as several patients were switched to the
other arm after the initial randomization, raising concerns of bias. Chen et al. reported no efficacy of HCQ
in virological clearance in a multicenter open-label
RCT (n ¼ 33) with 81% patients in the HCQ arm and
75% patients in the standard of care arm being RTPCR negative, with median time to negative PCR
being 5 and 11 days respectively, none of these measures reaching statistical significance [86]. This study
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had small sample size, younger patients with only
mild-moderate disease, and antivirals and antibacterials were used in the study. Another multicenter openlabel RCT (n ¼ 293) reported no difference in virological clearance at days 3 and 7 in patients treated
with HCQ compared to patients in the control arm
[87]. Unequal use of antivirals (more in HCQ arm),
short follow up, lack of placebo masking, lack of blinding and overrepresentations of younger patients and
healthcare workers (>80%) were some of the limitations of this study.
Use of HCQ ± AZ in 667 patients admitted with mild
to moderate COVID-19 was evaluated by Cavalcanti
et al. in a multicenter, randomized, non-blinded, openlabel, three-group, controlled trial using a 7-level
ordinal scale to evaluate the clinical status at day 15
[88]. Use of HCQ ± AZ was not associated with
improvement in clinical status, need for mechanical
ventilation, mortality rates, acute kidney injury and
thromboembolic complications. QTc prolongation was
observed in more patients treated with HCQ þ AZ
than those with HCQ alone or neither drug. This study
was unblinded. Patients requiring oxygen 4 l/min or
more were excluded from the trial. Protocol deviation
was noted, and many patients had previously received
HCQ and/or AZ 24 h prior to enrolment. Another single centre open label RCT evaluated the efficacy of
HCQ in 500 patients admitted with mild COVID-19
[89]. No difference was noted in PCR negativity at
Days 7 and/or 14, or the likelihood for disease progression between HCQ þ standard of care arm and
standard of care only arm. The study was unblinded
and patients were mostly younger (35.96 ± 11.2 years),
males (93.2), and all had mild infection with only 7.6%
having comorbid conditions, limiting the ability of this
trial to judge efficacy of HCQ in more severe cases.
The Randomized Evaluation of COVID-19 Therapy
(RECOVERY) trial was established to evaluate the efficacy of several drugs, including HCQ, for COVID-19
[90]. On 5 June 2020, enrolment into the HCQ arm of
the trial was stopped as preliminary data did not
show any beneficial effect of HCQ in hospitalized
patients with COVID-19. The preliminary results of this
large (1561 HCQ arm, 3155 usual care arm) randomized, controlled clinical trial show no difference in the
28-day mortality rate between the HCQ (268%) and
control (25%) arms [90]. Furthermore, patients in the
HCQ arm had a lower probability of discharge, with a
longer time to discharge, than patients in the control
arm, with a higher probability of needing mechanical
ventilation and death if mechanical ventilation was
not used. No beneficial effect of HCQ on hospital stay

duration was observed. As this trial included only hospitalized patients, with a mean duration of symptoms
of 9 days and more than 75% needing some form of
oxygen supplementation, the effects of HCQ earlier in
the course of infection in patients with less severe illness could not be assessed. In another randomized,
double-blind, placebo-controlled clinical trial evaluating the efficacy of HCQ among 423 outpatients with
early COVID-19, the use of HCQ was not associated
with reductions in the severity or duration of symptoms [91]. There was no statistically significant difference in hospitalizations or deaths between arms. This
study was limited by the lack of cases with confirmed
SARS-CoV-2 infection, with a PCR test performed on
only 58% of the participants and 16% participants
with a negative PCR test contributing to the data. The
participants in this study were mostly “low-risk” with a
median age of 40 years, 68% with no comorbidities,
and only 3% being African-Americans, which limit the
ability of this trial to inform the efficacy of HCQ for
severe COVID-19 infection in higher-risk populations.
On 20 June 2020, The National Institutes of Health
stopped the clinical trial to evaluate safety and efficacy of HCQ in patients hospitalized with COVID-19
after interim results did not show any benefit of HCQ
compared to placebo [92]. On 4 July 2020, WHO discontinued the HCQ arm of the SOLIDARITY trial after
reviewing the interim results, which showed no mortality benefit of HCQ in hospitalized patients with
COVID-19 compared with the standard of care [93,94].

Studies suggesting no prophylactic efficacy of
HCQ for COVID-19
In a randomized, placebo-controlled, double-blinded
trial of HCQ as a postexposure prophylactic initiated
within 4 days after moderate- to high-risk exposure,
HCQ was not associated with the prevention of illness
compatible with COVID-19 [95]. This trial was limited
by case definition (PCR confirmed or clinically compatible) and a lack of uniform PCR testing. The risk of
asymptomatic infections could not be assessed owing
to the lack of testing. Although patients in the HCQ
arm experienced more adverse effects than those in
the non-HCQ arm, most adverse effects were mild
with no reports of arrhythmias, although an asymptomatic increase in QTc was not assessed.
The data available suggest that patients with
rheumatic diseases (e.g. SLE) currently undergoing
HCQ therapy remain at risk for COVID-19 and are not
protected by HCQ use [96]. A group of 17 patients
with SLE on long-term HCQ therapy who contracted
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COVID-19 progressed to severe disease despite baseline treatment with HCQ [97]. Data from the COVID-19
Global Rheumatology Alliance Global Registry show
COVID-19 in 874 individuals with primary rheumatic
disease, 274% of whom were on HCQ or CQ before
COVID-19 diagnosis. There was no association
between the use of HCQ and risk of hospitalization or
serious infection in these patients, including those
with SLE [98,99].

Studies evaluating adverse effects of HCQ in
COVID-19
The effect of HCQ with or without AZ on QTc prolongation has been investigated in several observational and case studies [10–15]. Significant QTc
prolongation with HCQ with or without AZ was
reported in 90% of patients in intensive care with
COVID-19 (n ¼ 40) by Bessiere et al. [10]. Chorin et al.
reported severe QTc prolongation (>500 ms) in 11% of
patients (n ¼ 84) treated with HCQ þ AZ [11]. In anotherstudy, which included the previous 84 patients,
severe QTc prolongation in 23% of patients (n ¼ 251)
was reported; eight patients discontinued therapy
owing to severe QTc prolongation and one developed
polymorphic ventricular tachycardia, suspected as TdP,
needing cardioversion [12]. Ramireddy et al. reported
critical QTc prolongation in 12% of patients (n ¼ 490),
with greater prolongation with the combination of
HCQ and AZ than with either drug alone [13]. Saleh
et al. also reported greater QTc prolongation with the
combination of HCQ and AZ than with either drug
alone (n ¼ 210) [14]. Although these observational
studies indicate critical QTc prolongation secondary to
HCQ use in COVID-19, especially in combination with
AZ, they have several limitations, including lack of a
control arm and effects of confounding factors such as
underlying comorbidities, disease severity, and other
medications. A retrospective cohort analysis of 90
patients with COVID-19 treated with HCQ reported a
significant increase in QTc interval, with a greater
increase in those treated with AZ (53/90) [15].
Furthermore, this study reported one patient administered HCQ þ AZ who developed TdP and other ventricular arrhythmias needing lidocaine. The limitations
of this study included the lack of a control arm, short
follow-up, small sample size, and effects of confounding factors such as underlying comorbidities, disease
severity, and other medications. A transversal study
evaluating effect of HCQ in ambulatory and admitted
patients with COVID (n ¼ 219) reported a significant
but not clinically relevant increase in QTc from
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baseline of 416 ms to 423 ms [100] 48 h after treatment initiation with none of the participants showing
an increase of more than 25% in QTc. The limitations
of this study included the lack of a control arm, short
follow-up, and exclusion of more severe disease.
Finally, an analysis from 3 RCTs evaluating HCQ as
pre-exposure prophylaxis, post-exposure prophylaxis,
and early treatment in COVID-19 reported safety data
on HCQ in this population (n ¼ 2795) [101]. Patients
treated with HCQ experienced more adverse effects,
mostly gastrointestinal and mild. Only one patient in
the HCQ arm developed supraventricular tachycardia
and no cases of sudden cardiac death or ventricular
arrhythmias were noted, although specific effects of
HCQ on QTc were not evaluated. Limitations of this
analysis included inclusion of only outpatient and
mostly younger, healthcare worker participants with
less underlying comorbidities, thus excluding those
with more severe disease and more comorbidities.

Summary of available literature
This review of the available literature suggests a scarcity of well-conducted clinical trials on HCQ for
COVID-19 (Table 2). While the initial observational data
suggested possible efficacy of HCQ in COVID-19,
recent clinical trial data has largely been unable to
reproduce these results. However, several methodological drawbacks have been noted in the available literature so far. Further, the currently available data is
insufficient to definitively confirm or rule out cardiotoxicity from HCQ when used in COVID-19. However,
this concern retains significance as most critical
patients infected with SARS-CoV-2 have underlying
cardiac comorbidities [9]. Owing to the paucity of
research in COVID-19, recommendations for or against
therapy cannot be suggested in earnest [102]. It is
appropriate to remain mindful of potential cardiovascular risk when prescribing HCQ, especially to those
with comorbidities.
As early literature suggested the efficacy of HCQ
against COVID-19, several organizations [103,104] supported the cautionary use of this medication. For
example, the Food and Drug Administration (FDA)
approved HCQ for emergency use [103]. Although
these early studies were crucial steps, recent trials suggest that the purported benefits of this medication
may not outweigh the potentially life-threatening
adverse effects. Owing to the evolving literature, several agencies have now advised against HCQ administration. The Centre for Disease Control, FDA, European
Medical Agency, American College of Physicians,
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Infectious Disease Society of America, and National
Institutes of Health have publicly stated the need for
caution when prescribing HCQ for COVID-19 outside
hospital and clinical trial settings [105–110].

Conclusion
HCQ, initially an antimalarial agent, is used as an
immunomodulatory agent for managing several autoimmune diseases, for which its efficacy is linked to
inhibiting lysosomal antigen processing, MHC-II antigen presentation, and TLR functions. It is generally
well-tolerated although severe life-threatening adverse
effects have been reported. HCQ gained popularity as
a potential therapy for COVID-19, owing to in vitro
data suggesting its antiviral activities by interfering
with lysosomal functions. However, data on its efficacy
and safety in COVID-19 are still insufficient, with several methodological difficulties and small sample sizes.
Recent clinical trials suggest no role of HCQ in COVID19 treatment or prevention, and there are unanswered
questions about its cardiac safety in patients with
COVID-19. Until further randomized controlled trials
eliciting the efficacy and safety are available, HCQ use
in COVID-19 should be discouraged outside clinical trials under strict medical supervision. Although rapid
publication of small trials and observational analyses
are necessary during a global pandemic, well-performed clinical trials with better methodology will
best present reliable and valid data moving forward.
Further low-powered investigation will only continue
to cloud the overall information on this topic.
Although it may not be possible to perform flawless
clinical trials, researchers should plan future trials by
assessing the limitations of published studies to
achieve high-quality research with minimal bias and
few methodological errors.
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